EDMONTON, Alberta--(BUSINESS WIRE)--IMBiotechnologies Ltd. today announced that an oral presentation regarding the use of its lead product, Occlusin® 500 Embolization Microspheres (Occlusin 500), in benign prostatic hypertrophy (BPH) patients will be presented at the 2018 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting. Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting qualitative data assessing prostate tissue and Occlusin 500 using ultrasound in patients after prostatic artery embolization. The presentation entitled “Ultrasound detection of a biodegradable embolic microsphere after prostatic artery embolization” and will be given by Dr. Owen on Saturday, September 22nd.
About Occlusin 500
Occlusin 500 is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors. IMBiotechnologies is currently seeking Health Canada approval for Occlusin 500.
About IMBiotechnologies Ltd.
IMBiotechnologies is a privately held Canadian medical device company located in Edmonton, Alberta focused on the commercialization of medical products in the area embolotherapy.
Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.